Global Market Study on Non-Melanoma Skin Cancer Treatment: Radiation Therapy to Remain Most Attractive Segment by Treatment Type During 2017 - 2025


Non Melanoma Skin Cancer Market
  • Published On : Aug-2017 |
  • Pages : 201 Pages |
  • Format :

Non-melanoma skin cancer is the most common form of skin cancer and it poses a significant economic burden on countries. Governmental bodies and regulatory authorities have become well-aware of this and now consider it an utmost priority to nip this healthcare concern in the bud itself. Persistence Market Research has drafted an in-depth report titled ‘Non-Melanoma Skin Cancer Treatment Market: Global Industry Analysis 2012 – 2016 and Forecast 2017 – 2025’. The report includes the historical analysis of the non-melanoma skin cancer treatment market and compares and contrasts it with the eight-year forecast period. The historical assessment serves as the perfect reference point to understand the future prospects of the non-melanoma skin cancer treatment market.

Fact-based research methodology helps us prepare industry leading reports

Persistence Market Research’s fundamentally strong research methodology is underpinned by extensive primary and secondary research that allows our analysts to extract all the necessary data related to the non-melanoma skin cancer treatment market. The data is validated by way of our company tools to glean qualitative and quantitative insights of the non-melanoma skin cancer treatment market.

The non-melanoma skin cancer treatment market report has a cohesive structure that allows our readers to easily transition from one section to another and get a comprehensive picture of the non-melanoma skin cancer treatment market. The initial chapters focus on the executive summary, market introduction, and market opportunity analysis. The summary includes a brief overview and some important facts of the non-melanoma skin cancer treatment market. Our experts have evaluated the non-melanoma skin cancer treatment market in exhaustive detail and given certain recommendations and opinions within this section that may prove immensely helpful to key stakeholders. The introduction is imperative to gain grassroots level knowledge of the non-melanoma skin cancer treatment market as it comprises the taxonomy and a concise definition of the non-melanoma skin cancer treatment market. The market opportunity analysis provides a holistic picture of the non-melanoma skin cancer treatment market.

Non-Melanoma Skin Cancer Treatment Market – Taxonomy

Treatment Type

  • Radiation Therapy
    • External Beam Radiation Therapy
    • Electronic Brachytherapy
    • Superficial Radiation Therapy
  • Chemotherapy
  • Photodynamic Therapy

Region

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Indication

  • Basal Cell Carcinoma
  • Squamous Cell Carcinoma

End User

  • Hospitals
  • Ambulatory Surgical Centers
  • Specialty Clinics

The subsequent chapters touch on the all-important market dynamics prevalent in the non-melanoma skin cancer treatment market. This section can be expected to deliver detailed information on the historical and current non-melanoma skin cancer treatment market size in strategic countries across diverse segments and an impact analysis of the regional DROTs. The market presence of the representative market participants in terms of the intensity concludes this portion of the non-melanoma skin cancer treatment market report.

As a new entrant seeking to enter the non-melanoma skin cancer treatment market or as an incumbent trying to change your go-to market strategies, a thorough competitive study is absolutely critical. Our competition landscape section has all the insights you could possibly need on your immediate competition in the non-melanoma skin cancer treatment market. We have highlighted detailed company profiles of some of the largest companies actively involved in the non-melanoma skin cancer treatment market by mentioning key financials, strategies adopted and recent company developments in the non-melanoma skin cancer treatment market. It is thus possible for our readers to conduct a rigorous competitive SWOT analysis.

A crucial section of the non-melanoma skin cancer treatment market report consists of a historical analysis and forecast of the non-melanoma skin cancer treatment market on the basis of treatment type, region, indication, and end user. This is where we present a trend analysis, historical market size, key market insights for the period 2012-2016 in tandem with the forecast for 2017-2025. We have taken the help of useful metrics such as CAGR, Y-o-Y growth rate, absolute and incremental dollar opportunity so that our readers can rely on our report for their long-term business decisions.

Government initiatives to raise awareness of non-melanoma skin cancer

Non-melanoma skin cancer is usually treated as a simple lesion in the initial stages but if not treated properly, it can quickly mushroom and spread to other body parts. Government authorities and regulatory bodies are working overtime to educate people about non-melanoma skin cancer and its debilitating effect on the nation’s economy. This is particularly in the developed world. For e.g. – Cancer Council Australia has unveiled the SunSmart program to raise awareness of non-melanoma skin cancer. This could not be done sooner as Australia suffers a great deal from non-melanoma skin cancer and has the highest prevalence in the APAC region. The Australian Institute of Health and Welfare estimates that skin cancer is the largest cancer diagnosed in the country and nearly 1800 people lost their lives to it in 2016. The A&Z non-melanoma skin cancer treatment market is anticipated to be valued at more than US$ 705 Mn at the end of the forecast period making it larger than the rest of the APAC region combined.

Radiation therapy dominates non-melanoma skin cancer treatment market

Radiation therapy has a market share approaching 90% in the non-melanoma skin cancer treatment market in 2017 itself and is unlikely to cede this commanding position anytime soon. Radiation therapy has a value of approx. US$ 4.8 Bn by end 2025 making it considerably larger than both chemotherapy and photodynamic therapy. Within radiation therapy, external beam radiation therapy is currently the largest in terms of market value. However, the highest CAGR of 9.6% for the period 2017-2025 is anticipated to be witnessed in the superficial radiation therapy segment as this newer treatment has relatively lesser side-effects making it preferable for patient health in the long run. The market attractiveness of radiation therapy in the non-melanoma skin cancer treatment market is expected to be 2.7 and the development of portable radiation therapy devices should further propel the non-melanoma skin cancer treatment market.

non melanoma skin cancer treatment market

Numerous complications linked to conventional radiation therapy

Radiation therapy is used to treat non-melanoma skin cancer lesions in cases where surgery is not possible such as the nose tip, eyelids, and other extremities. Unfortunately, radiation therapy causes serious side-effects depending on the treatment area size, radiation dose, and exposure duration. Some of the complications include edema, skin peeling, skin problems, and hair loss. All these challenges restrain the growth of radiation therapy in the non-melanoma skin cancer treatment market.

Superficial radiation therapy adopted in clinics for lesser side-effects

The development of standalone radiation therapy machines has led to their widespread acceptance in dermatology clinics to treat non-melanoma skin cancer. These highly portable devices are used because they have comparatively lesser side-effects. Sensus Healthcare has created SRT radiation therapy devices to treat non-melanoma skin cancer as they are a highly effective form of treatment with much lesser side-effects. These devices have the added benefit of being more economical compared to conventional radiation therapy devices. Sensus Healthcare has sold more than 300 superficial radiation therapy devices in the U.S. alone and this number is increasing by the day.

Company Profiles

  • Almirall S.A.
  • Boehringer Ingelheim GmbH 
  • Bristol-Myers Squibb Company 
  • Eli Lilly and Company 
  • Elekta AB 
  • F. Hoffmann-La Roche Ltd. 
  • Merck & Co., Inc.
  • Novartis AG
  • Mylan NV 
  • Sun Pharmaceutical Industries Ltd.
  • Varian Medical Systems, Inc.
  • Sensus Healthcare 
  • iCAD, Inc.
  • Accuray, Inc.
  • Ion Beam Applications SA
  • Others.
Back To Top